Glitazones are the new categories of insulin sensitizers, which are currently preferred over other hypoglycemic agents for Type 2 diabetes therapy, because of their positive effects on glucose level, insulin sensitivity, and the cardiometabolic profile [6]. This evidence concerns the gene INS and type 2 diabetes mellitus.